Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy

Table 5 Multivariate logistic regression analysis of factors associated with RP

Variables	Grade ≥ 2			Grade ≥ 3
Variables	OR	95% CI	p-value	OR	95% CI	p-value
Age (≥70/<70)	1.99	1.04-3.80	0.038	8.90	3.23-24.51	<0.001
Chemotherapy schedule (concurrent DP/concurrent NP/sequential)	1.45	1.01-2.07	0.041	1.98	1.16-3.39	0.013
Response (PR + CR/others)	1.06	0.53-2.14	0.870	4.39	1.12-17.24	0.034
PTV	1.004	1.002-1.007	0.001	1.005	1.001-1.009	0.021
MLD	1.42	1.28-1.58	<0.001	1.64	1.40-1.93	<0.001
Stage (IIIA/IIIB)	1.28	0.72-2.26	0.405	0.85	0.36-2.01	0.705
CTV location (left/right)	0.75	0.43-1.32	0.32	1.43	0.60-3.44	0.419
CTV location (upper/lower)	0.68	0.33-1.40	0.29	0.74	0.25-2.18	0.581

RP, radiation pneumonitis; PTV, planning target volume; MLD, mean lung dose; CR, complete response; PR, partial response; DP, docetaxel/cisplatin; NP, vinorelbine/cisplatin; CTV, clinical target volume.

ISSN: 1748-717X